Proteon Therapeutics Did not Meet Primary Endpoint In PATENCY-1 Trial, Data Suggests Secondary & Tertiary Endpoints May Improve Secondary Patency and vonapanitase May Improve Unassisted Fistula Use.
Paul Quintaro